About
Orange Biomed is a healthcare technology company dedicated to improving diabetes management through innovative point-of-care testing solutions. Founded in 2021 by two co-presidents from Duke University, the company focuses on enhancing accessibility and accuracy in diabetes care, particularly for underserved populations. Its flagship product, the OBM rapid A1C, is the first pocket-sized device that measures glycated hemoglobin (A1C) using advanced microfluidic technology. This device allows for easy and affordable A1C testing with just one drop of blood, making it suitable for home use. In addition to product development, Orange Biomed is committed to community health initiatives, such as the “M.A.P. YOUR HEALTH” campaign, which aims to raise awareness about chronic disease prevention. The company is also conducting studies to validate the accuracy of its testing device across diverse populations. With over USD 7.5 million in funding and multiple innovation awards, Orange Biomed is focused on transforming diabetes care and reducing disparities in diagnostic testing.
Technologies
Company Information
-
Employees 11
-
Founded 2021
Location
1730 Minor Ave, Seattle, Washington, United States, 98101-1405
